Related Experiment Video
Updated: Jun 12, 2026
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
Published on: February 2, 2013
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with
Chelsea Mayoh1,2, Jie Mao1, Jinhan Xie1,2
1Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, New South Wales, Australia.
Abstract:
For one-third of patients with pediatric cancer enrolled in precision medicine programs, molecular profiling does not result in a therapeutic recommendation. To identify potential strategies for treating these high-risk pediatric patients, we performed in vitro screening of 125 patient-derived samples against a library of 126 anticancer drugs. Tumor cell expansion did not influence drug responses, and 82% of the screens on expanded tumor cells were completed while the patients were still under clinical care. High-throughput drug screening (HTS) confirmed known associations between activating genomic alterations in NTRK, BRAF, and ALK and responses to matching targeted drugs. The in vitro results were further validated in patient-derived xenograft models in vivo and were consistent with clinical responses in treated patients. In addition, effective combinations could be predicted by correlating sensitivity profiles between drugs. Furthermore, molecular integration with HTS identified biomarkers of sensitivity to WEE1 and MEK inhibition. Incorporating HTS into precision medicine programs is a powerful tool to accelerate the improved identification of effective biomarker-driven therapeutic strategies for treating high-risk pediatric cancers.
Significance:
Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.
Insights
High-throughput drug screening (HTS) helps identify effective treatments for pediatric cancer patients when molecular profiling falls short. This approach accelerates personalized medicine by matching drugs to specific cancer profiles.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- Precision medicine in pediatric cancer often lacks therapeutic recommendations for a significant patient subset.
- Identifying effective treatments for high-risk pediatric cancers remains a critical challenge.
Purpose of the Study:
- To evaluate high-throughput drug screening (HTS) as a strategy for identifying therapeutic options for pediatric cancer patients.
- To integrate HTS with molecular profiling to enhance precision medicine.
Main Methods:
- In vitro screening of 125 patient-derived pediatric cancer samples against 126 anticancer drugs.
- Validation of in vitro findings using patient-derived xenograft models.
- Correlation of drug sensitivity profiles to predict effective drug combinations.
Main Results:
- HTS successfully identified drug responses, confirming known associations with genomic alterations (NTRK, BRAF, ALK).
- In vitro results were validated in vivo and correlated with clinical patient responses.
- Biomarkers for WEE1 and MEK inhibition sensitivity were identified through molecular integration with HTS.
Conclusions:
- Integrating HTS with molecular profiling significantly enhances precision medicine for pediatric cancers.
- This approach broadens therapeutic options and accelerates the identification of biomarker-driven treatments for high-risk pediatric cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...